ADC Therapeutics SA
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
ADCT$1.51-9.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
Table of Contents
ADC Therapeutics SA
CONSOLIDATED BALANCE SHEETS
(in thousands, except share amounts)
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $250,867 | $278,598 |
| Accounts receivable, net | 20,316 | 25,182 |
| Inventory | 18,387 | 16,177 |
| Prepaid expenses | 8,370 | 10,344 |
| Other current assets | 9,450 | 5,990 |
| Total current assets | 307,390 | 336,291 |
| Property and equipment, net | 5,075 | 5,622 |
| Operating lease right-of-use assets | 8,354 | 10,511 |
| Interest in joint venture | — | 1,647 |
| Other long-term assets | 1,161 | 711 |
| Total assets | $321,980 | $354,782 |
| LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY | ||
| Current liabilities | ||
| Accounts payable | $18,029 | $15,569 |
| Accrued expenses and other current liabilities | 62,440 | 52,101 |
| Total current liabilities | 80,469 | 67,670 |
| Deferred royalty obligation, long-term | 320,093 | 303,572 |
| Senior secured term loans | 113,632 | 112,730 |
| Operating lease liabilities, long-term | 7,995 | 10,180 |
| Other long-term liabilities | 2,433 | 8,879 |
| Total liabilities | 524,622 | 503,031 |
| Commitments and contingencies (Note 14) | ||
| Shareholders’ (deficit) equity | ||
| Common shares, at CHF 0.08 par value | 8,425 | 7,312 |
| Issued shares: 101,606,376 at December 31, 2024 and 89,041,946 at December 31, 2023; outstanding shares: 98,861,402 at December 31, 2024 and 82,293,137 at December 31, 2023 | ||
| Additional paid-in capital | 1,283,892 | 1,180,545 |
| Treasury shares | (220) | (541) |
| Accumulated other comprehensive loss | (1,421) | (93) |
| Accumulated deficit | (1,493,318) | (1,335,472) |
| Total shareholders’ (deficit) equity | (202,642) | (148,249) |
| Total liabilities and shareholders’ (deficit) equity | $321,980 | $354,782 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.